ORIC Pharmaceuticals (ORIC)
Advances two Phase 3 oncology candidates targeting drug-resistant prostate and lung cancers.
$13.22
vs last close−0.28 (−2.10%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 119.50% | 123.87M shares | |
|---|---|---|---|
| 189 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.04% | 1.08M shares | |
| 6 holders · as of Aug 28, 2026 | |||
| Adds to | 120.54% | ||
103.65M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 120.54%; nothing is left for Other.
13F, as of Jun 30, 2026
189 holders · 123.87M shares · 33 new positions · 114 increased · 43 reduced · 32 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Nextech Invest, Ltd. | 7.16M | 6.91% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.82M | 6.58% | +839.4K | Aug 7, 2026 |
| Ecor1 Capital, LLC | 6.73M | 6.49% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.62M | 6.38% | +1.23M | Aug 14, 2026 |
| Viking Global Investors LP | 5.13M | 4.95% | −697.8K | Aug 14, 2026 |
| State Street Corp | 4.89M | 4.72% | +1.19M | Aug 7, 2026 |
| Sr One Capital Management, LP | 4.62M | 4.45% | +100.5K | Aug 12, 2026 |
| VR Adviser, LLC | 4.32M | 4.17% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Nextech Crossover I GP S.a. r.l. | 8.40% | 7.16M | 13G | Aug 14, 2025 |
| Viking Global Investors LP | 7.80% | 8.26M | 13G | May 15, 2026 |
| EcoR1 Capital, LLC | 6.90% | 6.73M | 13G | Aug 5, 2025 |
| BlackRock, Inc. | 5.60% | 5.47M | 13G | Jan 21, 2026 |
| T. Rowe Price Associates, Inc. | 5.40% | 5.39M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Dominic Piscitelliofficer: Chief Financial Officer | Sale | 77,000 | $13.69 | 69,828 |
| Jul 24, 2026 | Richard A. Heymandirector | Sale · 2 lots | 13,100 | $12.02 | 244,972 |
| Jul 6, 2026 | Richard A. Heymandirector | Sale | 300 | $12.00 | 212,772 |
| Feb 24, 2026 | Dominic Piscitelliofficer: Chief Financial Officer | Sale | 52,000 | $13.51 | 68,148 |
| Jan 16, 2026 | Richard A. Heymandirector | Sale · 2 lots | 6,700 | $12.00 | 254,872 |
| Dec 16, 2025 | Jacob Chackodirector, officer: PRESIDENT AND CEO | Sale | 33,374 | $9.06 | 581,711 |
| Dec 16, 2025 | Dominic Piscitelliofficer: Chief Financial Officer | Sale | 10,720 | $9.06 | 68,148 |
| Dec 16, 2025 | Pratik S. Multaniofficer: Chief Medical Officer | Sale | 10,720 | $9.06 | 68,149 |
| Oct 6, 2025 | Jacob Chackodirector, officer: PRESIDENT AND CEO | Sale | 37,461 | $12.32 | 531,419 |
| Oct 6, 2025 | Dominic Piscitelliofficer: Chief Financial Officer | Sale | 11,000 | $14.52 | 48,317 |
House and Senate disclosures
Not reported.